Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Telomere Length Of Granulocytes Significantly Increases During The First Six Months Of Lenalidomide Treatment In Patients With Isolated 5q- Syndrome

Fabian Beier, MD, Ulrich Germing, MD, Guntram Büsche, MD, Patrick Ziegler, PhD, Stefan Wilop, MD, Lucia Vankann, Norbert Gattermann, MD, Uwe Platzbecker, MD, PhD, Aristoteles Giagounidis, MD, PhD, Katharina S. Götze, MD, Wolf-Karsten Hofmann, Detlef Haase, MD, PhD, Hans Kreipe, MD, Jens Panse, MD, Tim H. Brümmendorf, MD

Blood (2013) 122 (21): 2781.

https://doi.org/10.1182/blood.V122.21.2781.2781

Published: 2013

Journal Articles

Pomalidomide In MPN–associated Myelofibrosis With Cytopenia: Results Of The Mpnsg 01-09 Study

Blood (2013) 122 (21): 2822.

https://doi.org/10.1182/blood.V122.21.2822.2822

Published: 2013

Journal Articles

The Kinetic Of Bone Marrow Fibrosis Regression Predicts Outcome In Myelofibrosis Patients After Allogeneic SCT

Nicolaus Kröger, MD, Haefaa Alchalby, MD, Tatjana Zabelina, MD, Hans-Michael Kvasnicka, MD, Juergen Thiele, MD, PhD, Guntram Büsche, MD, Hans Kreipe, MD

Blood (2013) 122 (21): 2078.

https://doi.org/10.1182/blood.V122.21.2078.2078

Published: 2013

Journal Articles

RBC Transfusion Independence and Safety Profile of Lenalidomide 5 or 10 mg in Pts with Low- or Int-1-Risk MDS with Del5q: Results From a Randomized Phase III Trial (MDS-004).

Pierre Fenaux, Aristotle Giagounidis, Dominik Selleslag, MD, Odile Beyne-Rauzy, MD, PhD, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath, Moshe Mittelman, MD, Petra Muus, MD, PhD, Peter te Boekhorst, MD, PhD, Guillermo Sanz, MD, PhD, Consuelo del Cañizo, Agnes Guerci-Bresler, Brigitte Schlegelberger, M.D., Carlo Aul, Hans Kreipe, MD, Gudrun Goehring, Robert Knight, MD, John Francis, Tommy Fu, Eva Hellstrom-Lindberg, MD, PhD

Blood (2009) 114 (22): 944.

https://doi.org/10.1182/blood.V114.22.944.944

Published: 2009

Journal Articles

Severe Early-Onset Inflammatory Bowel Disease Caused by IL10 Receptor Deficiency Can Be Cured by Allogeneic Hematopoietic Stem Cell Transplantation.

Blood (2009) 114 (22): 713.

https://doi.org/10.1182/blood.V114.22.713.713

Published: 2009

Journal Articles

Patients with Del(5q) MDS Who Fail to Achieve Erythroid or Cytogenetic Remission After Treatment with Lenalidomide Have An Increased Risk for Clonal Evolution and AML Progression.

Gudrun Göhring, MD, Aristoteles Giagounidis, Guntram Büsche, MD, Hans Kreipe, MD, Martin Zimmermann, PhD, Eva Hellstrom-Lindberg, MD, PhD, Carlo Aul, Brigitte Schlegelberger, M.D.

Blood (2009) 114 (22): 3818.

https://doi.org/10.1182/blood.V114.22.3818.3818

Published: 2009

Journal Articles

Anti-Angiogenic in-Vivo Effect of Lenalidomide and Its Impact On Neoplastic and Non-Neoplastic Hematopoiesis in MDS with Del(5q) Chromosome Abnormality.

Guntram Buesche, MD, Stephanie Dieck, Aristoteles Giagounidis, MD, Gudrun Göhring, MD, Brigitte Schlegelberger, MD, Robert Knight, MD, Carlo Aul, MD, Hans Kreipe, MD

Blood (2009) 114 (22): 3800.

https://doi.org/10.1182/blood.V114.22.3800.3800

Published: 2009

Journal Articles

Long-Term Cytogenetic Follow-up of MDS Patients with 5q- Treated within the MDS-003 (CC-5013-MDS-003) Study: Evolution to Complex Clones and Progression to AML.

Gudrun Göhring, MD, Aristoteles Giagounidis, Carlo Aul, Guntram Büsche, MD, Hans Kreipe, MD, Eva Hellström-Lindberg, MD, PhD, Robert D. Knight, MD, Brigitte Schlegelberger, MD

Blood (2008) 112 (11): 1647.

https://doi.org/10.1182/blood.V112.11.1647.1647

Published: 2008

Journal Articles

Ectopic Expression of the Extracellular Domain of Mpl Is Sufficient to Induce a Hematopoietic Population Crisis

Daniel C. Wicke, Johann Meyer, Guntram Büsche, MD, Hans Kreipe, MD, Zhixiong Li, MD, Karl Welte, Matthias Ballmaier, Christopher Baum, Ute Modlich

Blood (2008) 112 (11): 2886.

https://doi.org/10.1182/blood.V112.11.2886.2886

Published: 2008

NARROW

Telomere Length Of Granulocytes Significantly Increases During The First Six Months Of Lenalidomide Treatment In Patients With Isolated 5q- Syndrome

Pomalidomide In MPN–associated Myelofibrosis With Cytopenia: Results Of The Mpnsg 01-09 Study

The Kinetic Of Bone Marrow Fibrosis Regression Predicts Outcome In Myelofibrosis Patients After Allogeneic SCT

RBC Transfusion Independence and Safety Profile of Lenalidomide 5 or 10 mg in Pts with Low- or Int-1-Risk MDS with Del5q: Results From a Randomized Phase III Trial (MDS-004).

Severe Early-Onset Inflammatory Bowel Disease Caused by IL10 Receptor Deficiency Can Be Cured by Allogeneic Hematopoietic Stem Cell Transplantation.

Patients with Del(5q) MDS Who Fail to Achieve Erythroid or Cytogenetic Remission After Treatment with Lenalidomide Have An Increased Risk for Clonal Evolution and AML Progression.

Anti-Angiogenic in-Vivo Effect of Lenalidomide and Its Impact On Neoplastic and Non-Neoplastic Hematopoiesis in MDS with Del(5q) Chromosome Abnormality.

Long-Term Cytogenetic Follow-up of MDS Patients with 5q- Treated within the MDS-003 (CC-5013-MDS-003) Study: Evolution to Complex Clones and Progression to AML.

Ectopic Expression of the Extracellular Domain of Mpl Is Sufficient to Induce a Hematopoietic Population Crisis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only